Combined DMARDS in rheumatoid arthritis: past, present and future.
The potential for combined therapy in rheumatoid arthritis is rapidly increasing considering the recent development of various new treatment modalities. However, an aggressive effort must be made to stage patients according to various clinical and immunological parameters. Only then can appropriate combined therapy be used effectively in this disease process. The development of such combined therapy could expand into other diseases such as scleroderma, systemic lupus erythematosus and multiple sclerosis.
Yocum
D E
DE
Department of Internal Medicine, Arizona Arthritis Center, University of Arizona, Tucson 84724.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003524:Cyclosporins / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D008727:Methotrexate